B · Normal
[Botuo Bio: The business of export products to the United States has resumed year-on-year growth] On September 7, Botuo Bio stated at the 2026 semi-annual performance briefing held on September 7 that the company's exchange losses were mainly due to the decline in the U.S. dollar exchange rate, and the exchange losses caused by the company's holdings of U.S. dollar assets increased significantly. The company will rationally allocate U.S. dollar assets and financial products, choose the opportunity to settle foreign exchange, and reduce the impact of the exchange rate on the company's profits. The company's current export business to the United States has resumed growth year-on-year.
Comments